2 weeks ago

India pharma sales jump 12.1% led by Sun, Zydus

India pharma sales jump 12.1% led by Sun, Zydus
India pharma rebounds with Sun, Zydus leading an overall 12.1% growth in July · financialexpress.com

In 2026, the medicine business in India is growing again after a few slow years.

In July, people bought about 12% more medicines than they did a year before.

A big reason is that some medicines got more expensive, and companies launched new medicines.

Another big reason is that medicines for diabetes are selling very fast.

These medicines are called GLP-1 drugs, and they are also used for weight loss.

Two companies, Zydus and Sun Pharma, grew faster than most others.

Almost every medicine company grew more than the whole market.

Only one company, called IPCA, grew slower because some of its medicines did not sell well.

Experts at the company Nomura say big medicine companies will keep growing by launching new products.

Key facts

Market growth (July 2026)
12.1% year on year
Fastest-growing companies
Zydus Lifesciences (20.8%), Sun Pharma (17.8%), Cipla (17.3%), Torrent Pharma (16.1%)
Growth drivers
Price increases ~6%, new launches 3.7%, volumes 2.3%
GLP-1 market (MAT July 2026)
Rs 2,213 crore, up from Rs 661 crore a year earlier
GLP-1 segment shares
Tirzepatide 63%, Semaglutide 32%
Generic Semaglutide users
~2.9 lakh patients, up 16% month on month
Nomura target prices
Sun Pharma Rs 2,400; Dr Reddy's Rs 1,740; Alkem Rs 6,890
Growth laggard
IPCA, due to weak anti-malarial and anti-infective sales

Quotes

Nomura

Research analyst at Nomura, the brokerage firm reporting the data

“"The recovery in growth rate is driven by the low volume in the base, a pick‑up in new launch contributions like GLP‑1 (~80bps) and a pick‑up in chronic therapies such as cardiac, neuro and strong growth in vitamin, mineral and nutritional supplements (VMNs) and oncology,"”
financialexpress.com

Sources

Related news